Sweden Breast Cancer Therapeutics Market Analysis Report [2022-30] I Insights10

Sweden Breast Cancer Therapeutics Market Analysis

$ 3999

The Sweden breast cancer therapeutics market is witnessing significant growth from $66 Mn in 2022 to $xx Mn in 2030 with a CAGR of xx% for the year 2022-2030. Advanced targeted therapies and the increasing prevalence of breast cancer are driving the market growth of Sweden's breast cancer therapeutics. The market is segmented by therapy, by cancer type, and by distribution channel. Some of the key players in Sweden's breast cancer therapeutics are MSD Sverige, Oncothyreon, and AstraZeneca.

ID: IN10SEPH031 CATEGORY: Pharmaceuticals GEOGRAPHY: Sweden AUTHOR: Parul Choudhary

Buy Now

Sweden Breast Cancer Therapeutics Market Executive Analysis

The Sweden breast cancer therapeutics market size is at around $66 Mn in 2022 and is projected to reach $xx Mn in 2030, exhibiting a CAGR of xx% during the forecast period. The cost of health and medical care as a %age of Sweden's GDP has been relatively consistent and is comparable to that of the majority of other European nations. In Sweden, healthcare expenses typically account for 11% of GDP. Regional and municipal taxes in Sweden make up the majority of the cost of healthcare and medical care. While patient fees only cover a small portion of expenses, contributions from the federal government are another source of support. In Sweden, healthcare is provided by both public and private organizations, and all are subject to the same laws.

According to the Swedish National Board of Health and Welfare, the nation experiences about 12,000 new cases of breast cancer each year. Around 85% of patients with breast cancer in Sweden survive for at least five years after their diagnosis, which is a high overall survival rate. Tamoxifen and aromatase inhibitors used in adjuvant hormone therapy have been shown to reduce the incidence of breast cancer recurrence by over 30% in Sweden. Despite this, more than half of patients with breast cancer stop receiving such treatment. Adjuvant hormone therapy should not be halted since it decreases the effectiveness of treatment, increasing the risk of cancer recurrence and mortality that might have otherwise been avoided. The new biological medication that the Swedish researchers had created was tested in order to inhibit the communication between connective tissue cells and tumour cells that is mediated by PDGF-CC. This caused the basal breast tumours to change into hormone-sensitive luminal breast cancers. This transition led to the tumours becoming very receptive to classical hormone therapy.

sweden breast cancer therapeutics market analysis

Market Dynamics

Market Growth Drivers

Due to their enhanced selectivity towards cancer cells and less off-target effects, targeted therapies are becoming increasingly important and are anticipated to support the expansion of the Sweden breast cancer therapeutics market revenue throughout the forecast period. Moreover, increased investment in R&D efforts to produce monoclonal antibodies and oral medicines, as well as the necessity to solve the complications of breast cancer chemotherapy, are some additional variables anticipated to propel breast cancer therapeutics market revenue growth in Sweden.

Market Restraints

The Sweden market for breast cancer therapeutics is being hampered by side effects caused by drug use. Long-term or short-term adverse effects of breast cancer medications can include headaches, dental difficulties, osteoporosis, heart problems, etc. Patients then rely on alternative or complementary medications to treat the adverse effects, which raises the overall cost of care. Furthermore, the persistence of some side effects deters patients from using breast cancer therapies, which has a detrimental influence on Sweden's breast cancer therapeutics market expansion.

Competitive Landscape

Key Players

Immedica Pharma (SWE)
Pharmetheus (SWE)
Karo Pharma (SWE)
MSD Sverige (SWE)
Oncothyreon
AstraZeneca
Sprint Bioscience
Genentech
Galena Biopharma

Healthcare Policies and Regulatory Landscape

Health services are available to everyone who lives in Sweden, regardless of nationality. The 21 Swedish counties are in charge of financing, procuring, and delivering health services, while the central government is in charge of regulation and oversight. The National Cancer Plan and the Swedish National Board of Health and Welfare are principally in charge of determining breast cancer healthcare policies in Sweden. The overarching objectives and plans for cancer treatment in Sweden are outlined in the National Cancer Plan, a government-led programme. It contains recommendations for patients with breast cancer in terms of early detection, diagnosis, therapy, and recovery. The strategy contains goals for lowering breast cancer incidence and mortality rates as well as enhancing patients' quality of life.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Breast Cancer Therapeutics Segmentation

By Therapy (Revenue, USD Billion):

Radiation Therapy
- Targeted Therapy
  - Ribociclib
  - Abemaciclib
  - Afinitor
  - Everolimus
  - Trastuzumab
  - Olaparib
  - Ado-Trastuzumab Emtansine
  - Palbociclib
  - Pertuzumab
  - Herceptin
  - Tykerb (Lapatinib)
  - Others
Hormonal Therapy
- Selective Estrogen Receptor Modulators (SERMs)
- Aromatase Inhibitors
- Estrogen Receptor Downregulators (ERDs)
Chemotherapy
- Taxanes
- Anthracyclines
- Anti-metabolites
- Alkylating Agents
Immunotherapy

By Cancer Type (Revenue, USD Billion):

Hormone Receptor
HER+

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.